CN106660998B - 吡唑基-3,4-二氢喹啉-2-酮醛固酮合酶抑制剂 - Google Patents

吡唑基-3,4-二氢喹啉-2-酮醛固酮合酶抑制剂 Download PDF

Info

Publication number
CN106660998B
CN106660998B CN201580043590.9A CN201580043590A CN106660998B CN 106660998 B CN106660998 B CN 106660998B CN 201580043590 A CN201580043590 A CN 201580043590A CN 106660998 B CN106660998 B CN 106660998B
Authority
CN
China
Prior art keywords
methyl
pyrazol
dihydroquinolin
fluoro
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580043590.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106660998A (zh
Inventor
约翰尼斯·埃比
库尔特·阿姆雷因
佰努瓦·霍恩斯普格
贝恩德·库恩
刘永福
汉斯·P·梅尔基
赖纳·E·马丁
亚历山大·V·迈韦格
谭雪菲
王利莎
李东波
吴俊�
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN106660998A publication Critical patent/CN106660998A/zh
Application granted granted Critical
Publication of CN106660998B publication Critical patent/CN106660998B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580043590.9A 2014-10-31 2015-10-28 吡唑基-3,4-二氢喹啉-2-酮醛固酮合酶抑制剂 Active CN106660998B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014090064 2014-10-31
CNPCT/CN2014/090064 2014-10-31
PCT/EP2015/074923 WO2016066663A1 (en) 2014-10-31 2015-10-28 Pyrazolyl-3,4-dihydroquinolin-2-one aldosterone synthase inhibitors

Publications (2)

Publication Number Publication Date
CN106660998A CN106660998A (zh) 2017-05-10
CN106660998B true CN106660998B (zh) 2019-10-25

Family

ID=54356342

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580043590.9A Active CN106660998B (zh) 2014-10-31 2015-10-28 吡唑基-3,4-二氢喹啉-2-酮醛固酮合酶抑制剂

Country Status (5)

Country Link
US (1) US9796702B2 (https=)
EP (1) EP3212631B1 (https=)
JP (1) JP6669734B2 (https=)
CN (1) CN106660998B (https=)
WO (1) WO2016066663A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103814021A (zh) * 2011-09-15 2014-05-21 霍夫曼-拉罗奇有限公司 新二氢喹啉-2-酮衍生物
WO2014135561A1 (en) * 2013-03-08 2014-09-12 F. Hoffmann-La Roche Ag New dihydroquinoline-2-one derivatives as aldosterone synthase (cyp1 1 b2 or cyp1 1 b1 ) inhibitors
WO2014139981A1 (en) * 2013-03-14 2014-09-18 F. Hoffmann-La Roche Ag Dihydroquinoline-2-one derivatives for use as aldosterone synthase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US9353081B2 (en) * 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103814021A (zh) * 2011-09-15 2014-05-21 霍夫曼-拉罗奇有限公司 新二氢喹啉-2-酮衍生物
WO2014135561A1 (en) * 2013-03-08 2014-09-12 F. Hoffmann-La Roche Ag New dihydroquinoline-2-one derivatives as aldosterone synthase (cyp1 1 b2 or cyp1 1 b1 ) inhibitors
WO2014139981A1 (en) * 2013-03-14 2014-09-18 F. Hoffmann-La Roche Ag Dihydroquinoline-2-one derivatives for use as aldosterone synthase inhibitors

Also Published As

Publication number Publication date
JP2017537056A (ja) 2017-12-14
EP3212631A1 (en) 2017-09-06
EP3212631B1 (en) 2020-02-12
WO2016066663A1 (en) 2016-05-06
US20170226085A1 (en) 2017-08-10
US9796702B2 (en) 2017-10-24
CN106660998A (zh) 2017-05-10
JP6669734B2 (ja) 2020-03-18

Similar Documents

Publication Publication Date Title
TWI642668B (zh) 新穎３，４－二氫－２ｈ－異喹啉－１－酮及２，３－二氫異吲哚－１－酮化合物
CN105143204B (zh) 3,4‑二氢‑2h‑异喹啉‑1‑酮和2,3‑二氢‑异吲哚‑1‑酮化合物
TWI704143B (zh) 新穎３,４-二氫-２ｈ-異喹啉-１-酮及２,３-二氫異吲哚-１-酮化合物
CN106660998B (zh) 吡唑基-3,4-二氢喹啉-2-酮醛固酮合酶抑制剂
CN106604917B (zh) 作为醛固酮合酶抑制剂的新型二氢喹啉吡唑基化合物
JP6626885B2 (ja) 新しいピリジニルオキシ及びフェニルオキシピラゾリル化合物
EP3212630B1 (en) New dihydroquinoline pyrazolyl compounds
HK1232542B (zh) 吡唑基-3，4-二氢喹啉-2-酮醛固酮合酶抑制剂
HK1232542A1 (en) Pyrazolyl-3,4-dihydroquinolin-2-one aldosterone synthase inhibitors
CN105143205B (zh) 新的3,4‑二氢‑2h‑异喹啉‑1‑酮和2,3‑二氢‑异吲哚‑1‑酮化合物
HK1232215B (zh) 作为醛固酮合酶抑制剂的新型二氢喹啉吡唑基化合物
HK1232887A1 (en) New dihydroquinoline pyrazolyl compounds
HK1232887B (zh) 新型二氢喹啉吡唑基化合物
HK1233250B (zh) 新的吡啶基氧基-和苯基氧基-吡唑基化合物
HK1213556B (en) New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1232542

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant